Loading…
The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study
BACKGROUND As dihydrotestosterone (DHT) is the most potent androgen in the prostate, inhibition of the 5α‐reductase isoenzymes, which convert testosterone to DHT, could be an appropriate target for the treatment of prostate cancer. METHODS Eighty‐one men with clinically localized prostate cancer rec...
Saved in:
| Published in: | The Prostate 2006-11, Vol.66 (15), p.1674-1685 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3779-8dfc0485620c1aa96a7f75e82c341b5883deabb5f8ac7015a0290014a6293ddf3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3779-8dfc0485620c1aa96a7f75e82c341b5883deabb5f8ac7015a0290014a6293ddf3 |
| container_end_page | 1685 |
| container_issue | 15 |
| container_start_page | 1674 |
| container_title | The Prostate |
| container_volume | 66 |
| creator | Gleave, M. Qian, J. Andreou, C. Pommerville, P. Chin, J. Casey, R. Steinhoff, G. Fleshner, N. Bostwick, D. Thomas, L. Rittmaster, R. |
| description | BACKGROUND
As dihydrotestosterone (DHT) is the most potent androgen in the prostate, inhibition of the 5α‐reductase isoenzymes, which convert testosterone to DHT, could be an appropriate target for the treatment of prostate cancer.
METHODS
Eighty‐one men with clinically localized prostate cancer received daily dutasteride 3.5 or 0.5 mg, or no therapy for 4 months before radical prostatectomy. Histopathological assessments were conducted on prostatectomy specimens.
RESULTS
Treatment with dutasteride was associated with reductions in serum and intraprostatic DHT of ≥90%, and a decrease in total prostate and tumor volumes. No effect of dutasteride was noted on Gleason grade. Histopathological effects on benign tissue were similar but less prominent than those seen with androgen ablation, whereas there was no significant difference in cancer histology among the groups.
CONCLUSIONS
Dutasteride treatment results in similar but less marked changes compared with androgen ablation. Prostate 66: 1674–1685, 2006. © 2006 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/pros.20499 |
| format | article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_pros_20499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PROS20499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3779-8dfc0485620c1aa96a7f75e82c341b5883deabb5f8ac7015a0290014a6293ddf3</originalsourceid><addsrcrecordid>eNp9kE1uUzEUhS1UJNLChBV4wgTJ7bWfHb83RBFNkSJaQYChdeMfxfQlL7IdtekmWAsb6ZpwSElnjCzb3zn33EPIWw7nHEBcbNKQzwXIrntBRhw6zQCkOiEjEBqY5I1-RU5z_glQcRAj8mu-9NSH4G3JdAi01KvbYk_V42-WvNvagtnTuF7GRSxDqp_1ofgUnafDmvaDxT4-eEf3owsWTy2urU9VnLd9NQ1pWFGkkq2GdVlWzLOELlbZUWLLsNrRXLZu95q8DNhn_-bpPCPfLj_OJ1dsdj39NPkwY7bRumOtCxZkq8YCLEfsxqiDVr4VtpF8odq2cR4XCxVatBq4QhBd3VniWHSNc6E5I-8PvrZmyMkHs0lxhWlnOJh9lWYfzvytssLvDvAGc80dUt0w5mdFK5SSoq0cP3B3sfe7_ziamy_XX_95s4Mm1lbvjxpMt2asG63Mj89TcyUln3az72bS_AGoVJa4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study</title><source>Wiley</source><creator>Gleave, M. ; Qian, J. ; Andreou, C. ; Pommerville, P. ; Chin, J. ; Casey, R. ; Steinhoff, G. ; Fleshner, N. ; Bostwick, D. ; Thomas, L. ; Rittmaster, R.</creator><creatorcontrib>Gleave, M. ; Qian, J. ; Andreou, C. ; Pommerville, P. ; Chin, J. ; Casey, R. ; Steinhoff, G. ; Fleshner, N. ; Bostwick, D. ; Thomas, L. ; Rittmaster, R. ; on behalf of the ARI40010 Study Team</creatorcontrib><description>BACKGROUND
As dihydrotestosterone (DHT) is the most potent androgen in the prostate, inhibition of the 5α‐reductase isoenzymes, which convert testosterone to DHT, could be an appropriate target for the treatment of prostate cancer.
METHODS
Eighty‐one men with clinically localized prostate cancer received daily dutasteride 3.5 or 0.5 mg, or no therapy for 4 months before radical prostatectomy. Histopathological assessments were conducted on prostatectomy specimens.
RESULTS
Treatment with dutasteride was associated with reductions in serum and intraprostatic DHT of ≥90%, and a decrease in total prostate and tumor volumes. No effect of dutasteride was noted on Gleason grade. Histopathological effects on benign tissue were similar but less prominent than those seen with androgen ablation, whereas there was no significant difference in cancer histology among the groups.
CONCLUSIONS
Dutasteride treatment results in similar but less marked changes compared with androgen ablation. Prostate 66: 1674–1685, 2006. © 2006 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.20499</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>5 alpha reductase ; apoptosis ; Biological and medical sciences ; Gleason score ; Gynecology. Andrology. Obstetrics ; Male genital diseases ; Medical sciences ; Nephrology. Urinary tract diseases ; proliferation ; prostate cancer ; treatment ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The Prostate, 2006-11, Vol.66 (15), p.1674-1685</ispartof><rights>Copyright © 2006 Wiley‐Liss, Inc.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3779-8dfc0485620c1aa96a7f75e82c341b5883deabb5f8ac7015a0290014a6293ddf3</citedby><cites>FETCH-LOGICAL-c3779-8dfc0485620c1aa96a7f75e82c341b5883deabb5f8ac7015a0290014a6293ddf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18255428$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Gleave, M.</creatorcontrib><creatorcontrib>Qian, J.</creatorcontrib><creatorcontrib>Andreou, C.</creatorcontrib><creatorcontrib>Pommerville, P.</creatorcontrib><creatorcontrib>Chin, J.</creatorcontrib><creatorcontrib>Casey, R.</creatorcontrib><creatorcontrib>Steinhoff, G.</creatorcontrib><creatorcontrib>Fleshner, N.</creatorcontrib><creatorcontrib>Bostwick, D.</creatorcontrib><creatorcontrib>Thomas, L.</creatorcontrib><creatorcontrib>Rittmaster, R.</creatorcontrib><creatorcontrib>on behalf of the ARI40010 Study Team</creatorcontrib><title>The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND
As dihydrotestosterone (DHT) is the most potent androgen in the prostate, inhibition of the 5α‐reductase isoenzymes, which convert testosterone to DHT, could be an appropriate target for the treatment of prostate cancer.
METHODS
Eighty‐one men with clinically localized prostate cancer received daily dutasteride 3.5 or 0.5 mg, or no therapy for 4 months before radical prostatectomy. Histopathological assessments were conducted on prostatectomy specimens.
RESULTS
Treatment with dutasteride was associated with reductions in serum and intraprostatic DHT of ≥90%, and a decrease in total prostate and tumor volumes. No effect of dutasteride was noted on Gleason grade. Histopathological effects on benign tissue were similar but less prominent than those seen with androgen ablation, whereas there was no significant difference in cancer histology among the groups.
CONCLUSIONS
Dutasteride treatment results in similar but less marked changes compared with androgen ablation. Prostate 66: 1674–1685, 2006. © 2006 Wiley‐Liss, Inc.</description><subject>5 alpha reductase</subject><subject>apoptosis</subject><subject>Biological and medical sciences</subject><subject>Gleason score</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>proliferation</subject><subject>prostate cancer</subject><subject>treatment</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp9kE1uUzEUhS1UJNLChBV4wgTJ7bWfHb83RBFNkSJaQYChdeMfxfQlL7IdtekmWAsb6ZpwSElnjCzb3zn33EPIWw7nHEBcbNKQzwXIrntBRhw6zQCkOiEjEBqY5I1-RU5z_glQcRAj8mu-9NSH4G3JdAi01KvbYk_V42-WvNvagtnTuF7GRSxDqp_1ofgUnafDmvaDxT4-eEf3owsWTy2urU9VnLd9NQ1pWFGkkq2GdVlWzLOELlbZUWLLsNrRXLZu95q8DNhn_-bpPCPfLj_OJ1dsdj39NPkwY7bRumOtCxZkq8YCLEfsxqiDVr4VtpF8odq2cR4XCxVatBq4QhBd3VniWHSNc6E5I-8PvrZmyMkHs0lxhWlnOJh9lWYfzvytssLvDvAGc80dUt0w5mdFK5SSoq0cP3B3sfe7_ziamy_XX_95s4Mm1lbvjxpMt2asG63Mj89TcyUln3az72bS_AGoVJa4</recordid><startdate>200611</startdate><enddate>200611</enddate><creator>Gleave, M.</creator><creator>Qian, J.</creator><creator>Andreou, C.</creator><creator>Pommerville, P.</creator><creator>Chin, J.</creator><creator>Casey, R.</creator><creator>Steinhoff, G.</creator><creator>Fleshner, N.</creator><creator>Bostwick, D.</creator><creator>Thomas, L.</creator><creator>Rittmaster, R.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200611</creationdate><title>The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study</title><author>Gleave, M. ; Qian, J. ; Andreou, C. ; Pommerville, P. ; Chin, J. ; Casey, R. ; Steinhoff, G. ; Fleshner, N. ; Bostwick, D. ; Thomas, L. ; Rittmaster, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3779-8dfc0485620c1aa96a7f75e82c341b5883deabb5f8ac7015a0290014a6293ddf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>5 alpha reductase</topic><topic>apoptosis</topic><topic>Biological and medical sciences</topic><topic>Gleason score</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>proliferation</topic><topic>prostate cancer</topic><topic>treatment</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gleave, M.</creatorcontrib><creatorcontrib>Qian, J.</creatorcontrib><creatorcontrib>Andreou, C.</creatorcontrib><creatorcontrib>Pommerville, P.</creatorcontrib><creatorcontrib>Chin, J.</creatorcontrib><creatorcontrib>Casey, R.</creatorcontrib><creatorcontrib>Steinhoff, G.</creatorcontrib><creatorcontrib>Fleshner, N.</creatorcontrib><creatorcontrib>Bostwick, D.</creatorcontrib><creatorcontrib>Thomas, L.</creatorcontrib><creatorcontrib>Rittmaster, R.</creatorcontrib><creatorcontrib>on behalf of the ARI40010 Study Team</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gleave, M.</au><au>Qian, J.</au><au>Andreou, C.</au><au>Pommerville, P.</au><au>Chin, J.</au><au>Casey, R.</au><au>Steinhoff, G.</au><au>Fleshner, N.</au><au>Bostwick, D.</au><au>Thomas, L.</au><au>Rittmaster, R.</au><aucorp>on behalf of the ARI40010 Study Team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2006-11</date><risdate>2006</risdate><volume>66</volume><issue>15</issue><spage>1674</spage><epage>1685</epage><pages>1674-1685</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND
As dihydrotestosterone (DHT) is the most potent androgen in the prostate, inhibition of the 5α‐reductase isoenzymes, which convert testosterone to DHT, could be an appropriate target for the treatment of prostate cancer.
METHODS
Eighty‐one men with clinically localized prostate cancer received daily dutasteride 3.5 or 0.5 mg, or no therapy for 4 months before radical prostatectomy. Histopathological assessments were conducted on prostatectomy specimens.
RESULTS
Treatment with dutasteride was associated with reductions in serum and intraprostatic DHT of ≥90%, and a decrease in total prostate and tumor volumes. No effect of dutasteride was noted on Gleason grade. Histopathological effects on benign tissue were similar but less prominent than those seen with androgen ablation, whereas there was no significant difference in cancer histology among the groups.
CONCLUSIONS
Dutasteride treatment results in similar but less marked changes compared with androgen ablation. Prostate 66: 1674–1685, 2006. © 2006 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><doi>10.1002/pros.20499</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2006-11, Vol.66 (15), p.1674-1685 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_pros_20499 |
| source | Wiley |
| subjects | 5 alpha reductase apoptosis Biological and medical sciences Gleason score Gynecology. Andrology. Obstetrics Male genital diseases Medical sciences Nephrology. Urinary tract diseases proliferation prostate cancer treatment Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T20%3A26%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effects%20of%20the%20dual%205%CE%B1-reductase%20inhibitor%20dutasteride%20on%20localized%20prostate%20cancer-results%20from%20a%204-month%20pre-radical%20prostatectomy%20study&rft.jtitle=The%20Prostate&rft.au=Gleave,%20M.&rft.aucorp=on%20behalf%20of%20the%20ARI40010%20Study%20Team&rft.date=2006-11&rft.volume=66&rft.issue=15&rft.spage=1674&rft.epage=1685&rft.pages=1674-1685&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.20499&rft_dat=%3Cwiley_cross%3EPROS20499%3C/wiley_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3779-8dfc0485620c1aa96a7f75e82c341b5883deabb5f8ac7015a0290014a6293ddf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |